Gulfstream Daily Brief

Regulatory intelligence and policy · Issue 001

Evidence standards move, and market status can move with them

Today’s brief centers on evidence expectations and regulatory adaptability. FDA has rewritten its hepatic impairment study framework, while MHRA has moved from questions about pivotal data to market action on avacopan and outlined powers that could alter how UK device rules evolve.

By Scott Morvay, Founder September 2, 2026 Official sources linked

FDA

FDA redraws hepatic impairment PK study expectations

FDA issued draft guidance for assessing how hepatic impairment affects the pharmacokinetics and, when appropriate, pharmacodynamics of drugs and therapeutic biological products. It recommends early assessment, sets clearer triggers for dedicated studies, and addresses population PK approaches, study design, analysis, dosage recommendations, and labeling. FDA also withdrew its May 2003 guidance. Comments are due December 1, 2026.

Read the official source

MHRA

MHRA stops new starts of Avacopan Vifor

MHRA concluded that Avacopan Vifor’s pivotal efficacy study can no longer be relied upon following concerns about data integrity and reliability. The agency suspended use, supply, and sale to new patients from September 1. Supply for existing patients is permitted during a six-month managed withdrawal, with revocation of the UK marketing authorisation intended for March 1, 2027. Clinicians should review current patients and consider alternatives.

Read the official source

MHRA

UK proposals point toward more adaptive device oversight

Three proposed Health Bill amendments would expand MHRA information-sharing powers, make it easier for legislation to reflect updated technical standards and international guidelines, and create enabling powers for a future risk-proportionate MHRA licensing route for medical devices, including software and AI products. The proposals make no immediate regulatory change. The UKCA regime remains in place while Parliament considers the amendments and any future model is developed through consultation.

Read the official source

Why this matters

The common thread is evidence durability. FDA’s draft brings organ impairment planning earlier into development and gives teams a new basis for protocol design, modeling, analysis, and labeling decisions. MHRA’s avacopan action shows how pivotal-data concerns can change market status after authorisation and trigger coordinated clinical, safety, supply, and communications work. Device sponsors should treat the Health Bill amendments as an early watch item, not an implementation trigger, and follow the parliamentary process and future consultations.

Scott Morvay

Founder, Gulfstream Intelligence

This brief provides general regulatory news and educational information. It is not legal or regulatory advice.